Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-ku, Sapporo, 060-8543, Japan.
Department of Nephrology, Teine Keijinkai Hospital, Sapporo, Japan.
BMC Nephrol. 2020 Nov 3;21(1):459. doi: 10.1186/s12882-020-02122-y.
Fatty acid-binding protein 4 (FABP4), but not FABP1 (liver-type FABP), is ectopically induced in injured glomerular endothelial cells, and urinary FABP4 (U-FABP4) level is associated with proteinuria and renal dysfunction in a general population.
The clinical significance of U-FABP4 was investigated in 81 patients (male/female: 43/38, age: 57 ± 17 years) who underwent kidney biopsy.
U-FABP4 was negatively correlated with estimated glomerular filtration rate (eGFR) (r = - 0.56, P < 0.01) and was positively correlated with age, blood pressure, triglycerides, proteinuria (r = 0.58, P < 0.01), plasma FABP4 and urinary FABP1 (U-FABP1) (r = 0.52, P < 0.01). Multivariable regression analysis showed that eGFR, proteinuria and U-FABP1 were independent predictors of U-FABP4. The level of U-FABP4, but not that of proteinuria, eGFR or U-FABP1, in minimal change nephrotic syndrome (MCNS) was significantly lower than the level in membranous nephropathy (MN) and that in diabetic nephropathy. Receiver operating characteristic curve analysis indicated that U-FABP4 level ≤ 0.78 μg/gCr predicted MCNS in patients who had nephrotic-range proteinuria with a high level of accuracy. When divided by the median value of U-FABP4 at baseline in 33 of the 81 patients who could be followed up, the yearly change (post-pre) in eGFR in the low U-FABP4 group was significantly greater than that in the high U-FABP4 group (median: 11.0 vs. -5.0 mL/min/1.73m/year).
U-FABP4 level is independently associated with proteinuria and renal dysfunction in patients with glomerular kidney disease. A low U-FABP4 level may predict MCNS in patients with nephrotic syndrome and would be a useful biomarker for differential diagnosis of MCNS and MN, which are common causes of nephrotic syndrome.
脂肪酸结合蛋白 4(FABP4)而非 FABP1(肝型 FABP)在外伤性肾小球内皮细胞中异位诱导,尿 FABP4(U-FABP4)水平与普通人群中的蛋白尿和肾功能障碍相关。
对 81 例(男/女:43/38,年龄:57±17 岁)接受肾活检的患者进行了 U-FABP4 的临床意义研究。
U-FABP4 与估算肾小球滤过率(eGFR)呈负相关(r=-0.56,P<0.01),与年龄、血压、甘油三酯、蛋白尿(r=0.58,P<0.01)、血浆 FABP4 和尿 FABP1(U-FABP1)呈正相关(r=0.52,P<0.01)。多元回归分析表明,eGFR、蛋白尿和 U-FABP1 是 U-FABP4 的独立预测因子。微小病变性肾病综合征(MCNS)患者的 U-FABP4 水平,而不是蛋白尿、eGFR 或 U-FABP1 水平,显著低于膜性肾病(MN)和糖尿病肾病患者。受试者工作特征曲线分析表明,U-FABP4 水平≤0.78μg/gCr 可准确预测有大量蛋白尿的肾病综合征患者为 MCNS。在 81 例可随访的患者中,根据 33 例患者基线 U-FABP4 中位数将患者分组,低 U-FABP4 组的 eGFR 年变化(后前)明显大于高 U-FABP4 组(中位数:11.0 与-5.0 mL/min/1.73m/年)。
U-FABP4 水平与肾小球疾病患者的蛋白尿和肾功能障碍独立相关。低 U-FABP4 水平可能预测肾病综合征患者的 MCNS,是 MCNS 和 MN (常见的肾病综合征病因)鉴别诊断的有用生物标志物。